We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of an Antioxidant Formulation on Ocular Blood Flow

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01930487
First Posted: August 29, 2013
Last Update Posted: December 5, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
ScienceBased Health
  Purpose

The objective is to evaluate the effects of an antioxidant formula versus placebo on ocular blood flow in a randomized double-blind, crossover design.

Based upon preliminary data, it is hypothesized that a dietary supplement containing a variety of ingredients with antioxidant properties will, compared to placebo, increase ocular perfusion pressure, retrobulbar, retinal capillary and choroidal blood flow, and maintain these effects over the course of the treatment period.


Condition Intervention
Primary Open Angle Glaucoma Dietary Supplement: dietary supplement with antioxidants Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effects of an Antioxidant Formulation on Intraocular Pressure, Ocular Perfusion Pressure, Retrobulbar, Retinal Capillary and Choroidal Blood Flow

Resource links provided by NLM:


Further study details as provided by ScienceBased Health:

Primary Outcome Measures:
  • Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in superior retinal capillary blood flow (% zero pixels or % avascular tissue) using Heidelberg Retinal Flowmeter (HRF)

  • Change in Inferior Retinal Capillary Blood Flow (% Zero Pixels) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in inferior retinal capillary blood flow (% zero pixels or % avascular tissue) using Heidelberg Retinal Flowmeter (HRF)


Secondary Outcome Measures:
  • Change in Ocular Perfusion Pressure [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ocular perfusion pressure (2/3 Mean arterial pressure - intraocular pressure)

  • Change in Ophthalmic Artery Peak Systolic Blood Flow Velocity (cm/s) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ophthalmic artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI)

  • Change in Central Retinal Artery Peak Systolic Blood Flow Velocity (cm/s) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in central retinal artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI)

  • Change in Nasal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in nasal posterior ciliary artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI)

  • Change in Temporal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in temporal posterior ciliary artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI)

  • Change in Ophthalmic Artery End Diastolic Blood Flow Velocity (cm/s) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ophthalmic artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI)

  • Change in Central Retinal Artery End Diastolic Blood Flow Velocity (cm/s) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in central retinal artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI)

  • Change in Nasal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in nasal posterior ciliary artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI)

  • Change in Temporal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in temporal posterior ciliary artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI)

  • Change in Ophthalmic Artery Blood Flow - Vascular Resistance (Ratio) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ophthalmic artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI)

  • Change in Central Retinal Artery Blood Flow - Vascular Resistance (Ratio) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in central retinal artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI)

  • Change in Nasal Posterior Ciliary Artery Blood Flow - Vascular Resistance (Ratio) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in nasal posterior ciliary artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI)

  • Change in Temporal Posterior Ciliary Artery Blood Flow - Vascular Resistance (Ratio) [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in temporal posterior ciliary artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI)

  • Change in Ophthalmic Artery Peak Systolic Blood Flow Velocity (cm/s) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ophthalmic artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Ophthalmic Artery Peak Systolic Blood Flow Velocity (cm/s) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ophthalmic artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Central Retinal Artery Peak Systolic Blood Flow Velocity (cm/s) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in central retinal artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Central Retinal Artery Peak Systolic Blood Flow Velocity (cm/s) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in central retinal artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Nasal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in nasal posterior ciliary artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Nasal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in nasal posterior ciliary artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Temporal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in temporal posterior ciliary artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Temporal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in temporal posterior ciliary artery peak systolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Ophthalmic Artery End Diastolic Blood Flow Velocity (cm/s) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ophthalmic artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Ophthalmic Artery End Diastolic Blood Flow Velocity (cm/s) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ophthalmic artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Central Retinal Artery End Diastolic Blood Flow Velocity (cm/s) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in central retinal artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Central Retinal Artery End Diastolic Blood Flow Velocity (cm/s) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in central retinal artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Nasal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in nasal posterior ciliary artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Nasal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in nasal posterior ciliary artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Temporal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in temporal posterior ciliary artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Temporal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in temporal posterior ciliary artery end diastolic blood flow velocity (cm/s) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Ophthalmic Artery Blood Flow - Vascular Resistance (Ratio) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ophthalmic artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Ophthalmic Artery Blood Flow - Vascular Resistance (Ratio) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in ophthalmic artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Central Retinal Artery Blood Flow - Vascular Resistance (Ratio) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in central retinal artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Central Retinal Artery Blood Flow - Vascular Resistance (Ratio) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in central retinal artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Nasal Posterior Artery Blood Flow - Vascular Resistance (Ratio) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in nasal posterior artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Nasal Posterior Artery Blood Flow - Vascular Resistance (Ratio) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in nasal posterior artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Temporal Posterior Artery Blood Flow - Vascular Resistance (Ratio) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in temporal posterior artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI) in patients with type 2 diabetes

  • Change in Temporal Posterior Artery Blood Flow - Vascular Resistance (Ratio) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in temporal posterior artery blood flow - vascular resistance (ratio) using color Doppler imaging (CDI) in patients without type 2 diabetes

  • Change in Ocular Perfusion Pressure - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in Ocular perfusion pressure in patients with type 2 diabetes

  • Change in Ocular Perfusion Pressure - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in Ocular perfusion pressure in patients without type 2 diabetes

  • Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in superior retinal capillary blood flow (% zero pixels or % avascular tissue) using Heidelberg Retinal Flowmeter (HRF) in patients with type 2 diabetes

  • Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in superior retinal capillary blood flow (% zero pixels or % avascular tissue) using Heidelberg Retinal Flowmeter (HRF) in patients without type 2 diabetes

  • Change in Inferior Retinal Capillary Blood Flow (% Zero Pixels) - DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in inferior retinal capillary blood flow (% zero pixels or % avascular tissue) using Heidelberg Retinal Flowmeter (HRF) in patients with type 2 diabetes

  • Change in Inferior Retinal Capillary Blood Flow (% Zero Pixels) - No DM [ Time Frame: baseline and 30 days ]
    change (post-treatment - pre-treatment) in inferior retinal capillary blood flow (% zero pixels or % avascular tissue) using Heidelberg Retinal Flowmeter (HRF) in patients without type 2 diabetes


Enrollment: 47
Study Start Date: August 2013
Study Completion Date: August 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: supplement w/ antioxidants then placebo
dietary supplement with antioxidants, followed by placebo supplement
Dietary Supplement: dietary supplement with antioxidants
Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
Other Name: Optic Nerve Formula
Dietary Supplement: Placebo
Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
Experimental: placebo then supplement w/ antioxidants
placebo supplement, followed by dietary supplement with antioxidants
Dietary Supplement: dietary supplement with antioxidants
Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
Other Name: Optic Nerve Formula
Dietary Supplement: Placebo
Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 30 years or older.
  • Confirmed diagnosis of open angle glaucoma by glaucoma specialist in the study eye, as evidenced from criteria representative of glaucomatous optic nerve damage such as specific optic disc or retinal nerve fiber layer structural abnormalities and/or visual field abnormalities.
  • Best corrected visual acuity at 20/60 or better in study eye.
  • Willingness to avoid caffeine and smoking for 12 hours before and during the study visits.

Exclusion Criteria:

  • History of acute angle-closure or a narrow, occluding of anterior chamber angle by gonioscopy.
  • History of chronic or recurrent inflammatory eye diseases or signs of intraocular trauma and/or unreliable applanation tonometry.
  • Severe, unstable or uncontrolled cardiovascular, renal or pulmonary disease
  • History of/or current renal or hepatic impairment.
  • History of/or current bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiogenic shock.
  • Recent surgery or surgery planned near study timeline
  • History of bleeding disorder
  • Use of blood thinning medications
  • Use of specified dietary supplements for three weeks prior to study entry and throughout study period.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01930487


Locations
United States, Indiana
Glick Eye Institute, Ocular Vascular Research Center, Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
ScienceBased Health
Investigators
Principal Investigator: Alon Harris, PhD Professor of Ophthalmology, Professor of Cellular and Integrative Physiology, Director Clinical Research Glick Eye Institute, Indiana University Medical Center
  More Information

Responsible Party: ScienceBased Health
ClinicalTrials.gov Identifier: NCT01930487     History of Changes
Other Study ID Numbers: 007
First Submitted: August 9, 2013
First Posted: August 29, 2013
Results First Submitted: May 31, 2016
Results First Posted: December 5, 2016
Last Update Posted: December 5, 2016
Last Verified: January 2016

Keywords provided by ScienceBased Health:
Primary open angle glaucoma
intraocular pressure
ocular perfusion pressure
retrobulbar blood flow
retinal capillary blood flow
choroidal blood flow

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs